Uroplasty Announces Issuance of New Apparatus Patent for the UrgentÂ® PC Neuromodulation System Stimulator
MINNEAPOLIS, Nov., 9, 2011 /PRNewswire/ — Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced the issuance of United States Patent No. 8,046,082 covering the stimulator used in the UrgentÂ® PC Neuromodulation System. The Urgent PC Neuromodulation System is an office-based, non-surgical system, used to treat overactive bladder syndrome (OAB) and the associated symptoms of urinary urge incontinence, urinary urgency and urinary frequency. The new patent covers the reusable UrgentÂ® PC stimulator. When connected to a thin needle electrode near the ankle to access the tibial nerve, the stimulator delivers current to the sacral nerve plexus that controls bladder and pelvic floor function.
“This newly-issued patent further strengthens our patent position on the Urgent PC System and reinforces our commitment to this product,” said David Kaysen, President and CEO of Uroplasty. “We are very pleased that the United States Patent Office has awarded this apparatus patent on the unique stimulator used in our Urgent PC System. Our broad intellectual property portfolio, applicable to the Urgent PC System and its components, now includes apparatus, method, and system patents.”
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in
The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our UrgentÂ® PC Neuromodulation System, the only FDA-cleared neuromodulation system that delivers posterior tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer MacroplastiqueÂ® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.
For Further Information: Uroplasty, Inc. EVC Group --------------- --------- Doug Sherk/Jenifer Kirtland David Kaysen, President and CEO, or (Investors), 415.568.9349 Medi Jiwani, Vice President, CFO, Treasurer Chris Gale (Media), 646.201.5431 952.426.6140
SOURCE Uroplasty, Inc.